Medical expertise is growing with OmniaMed and DPE

Munich, July 2, 2013 – Funds advised by DPE Deutsche Private Equity GmbH (“DPE”) invest in the fast growing market for continuous medical education (CME”) by acquiring OmniaMed Group (“OmniaMed”) from US based MC Holding Corporation. The management team around Martina Schreck and Jonathan Morely will become significant shareholders in OmniaMed and continue to lead the group’s operations to ensure a sustainable development. DPE is a Munich-based investor focused on long-term growth investments in small and medium-sized companies in Germany, Austria and Switzerland. DPE and MC Holding Corporation agreed not to disclose any contractual details of the transaction.

OmniaMed, headquartered in Munich (D) and Sutton (UK), respectively, is one of two market leaders in Germany and the market leader in the UK for CME services. OmniaMed runs live medical educational conferences for primary and secondary physicians, nurses and allied healthcare practitioners (HCPs). The Group organizes more than 150 one-day events for approximately 14.000 HCPs p.a. across Germany and the UK, attracting top quality doctors as well as Tier 1 key opinion leaders as event speakers. The educational content is free of any promotional information and is presented by independent speakers.

Pharmaceutical companies support these conferences as it provides them with the opportunity to inform and interact with practitioners about existing and new drugs as well as any news associated therewith. Pharma companies increasingly prefer this marketing format over traditional channels in order to best comply with legal regulations, benefit from the concentration of a highly relevant target group and increase the flexibility of their fixed cost base.

Marc Thiery, managing partner at DPE, said “we are very excited to back a strong management team that has built OmniaMed to what has become a market leader in CME in Germany and the UK”. Guido Prehn, Partner at DPE, further added, “we are convinced that OmniaMed will continue to be a driver of innovative value-added services to the pharma industry and see international growth potential for the business model”.

The acquirer was advised by B-LUE Management Consulting, Mazars, Clifford Chance and P+P Pöllath + Partners.